Search research articles
Contact Us
Filters
Showing results (101-110 of 128) with videos related to
Page
of 13
Sort By:
The Lancet. Haematology
|
March 4, 2024
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
Michiel Coppens, Steven W Pipe, Wolfgang Miesbach, et al.
The New England Journal of Medicine
|
December 8, 2025
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B
Steven W Pipe, Wolfgang Miesbach, Michael Recht, et al.
Molecular Therapy. Methods & Clinical Development
|
September 19, 2025
Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study
Robert Klamroth, Michael Recht, Nigel S Key, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 28, 2024
Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B
Niamh O'Connell, Paul van der Valk, Sandra Le Quellec, et al.
Blood Advances
|
April 6, 2025
Completion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years
Annette von Drygalski, Esteban Gomez, Adam Giermasz, et al.
The Journal of Surgical Research
|
July 16, 2025
Patient Perspectives on Weight Management and Wellness After Liver Transplantation: A Convergent Mixed Methods Study
Natalia Rodriguez-Payan, Srilakshmi Atthota, Maria P Cote, et al.
Biological Psychiatry
|
August 8, 2015
Stress Enables Reinforcement-Elicited Serotonergic Consolidation of Fear Memory
Michael V Baratta, Suhasa B Kodandaramaiah, Patrick E Monahan, et al.
Journal of Biomolecular Screening
|
June 2, 2009
Best practices in compound management for preserving compound integrity and accurately providing samples for assays
Sandra L Matson, Moneesh Chatterjee, David A Stock, et al.
Blood Advances
|
December 9, 2022
Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
Annette von Drygalski, Esteban Gomez, Adam Giermasz, et al.
Transfusion
|
May 11, 2013
Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates
J Michael Soucie, Paul E Monahan, Roshni Kulkarni, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 128) with videos related to
Sort By:
Page
of 13
The Lancet. Haematology
|
March 4, 2024
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
Michiel Coppens, Steven W Pipe, Wolfgang Miesbach, et al.
The New England Journal of Medicine
|
December 8, 2025
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B
Steven W Pipe, Wolfgang Miesbach, Michael Recht, et al.
Molecular Therapy. Methods & Clinical Development
|
September 19, 2025
Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study
Robert Klamroth, Michael Recht, Nigel S Key, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 28, 2024
Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B
Niamh O'Connell, Paul van der Valk, Sandra Le Quellec, et al.
Blood Advances
|
April 6, 2025
Completion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years
Annette von Drygalski, Esteban Gomez, Adam Giermasz, et al.
The Journal of Surgical Research
|
July 16, 2025
Patient Perspectives on Weight Management and Wellness After Liver Transplantation: A Convergent Mixed Methods Study
Natalia Rodriguez-Payan, Srilakshmi Atthota, Maria P Cote, et al.
Biological Psychiatry
|
August 8, 2015
Stress Enables Reinforcement-Elicited Serotonergic Consolidation of Fear Memory
Michael V Baratta, Suhasa B Kodandaramaiah, Patrick E Monahan, et al.
Journal of Biomolecular Screening
|
June 2, 2009
Best practices in compound management for preserving compound integrity and accurately providing samples for assays
Sandra L Matson, Moneesh Chatterjee, David A Stock, et al.
Blood Advances
|
December 9, 2022
Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
Annette von Drygalski, Esteban Gomez, Adam Giermasz, et al.
Transfusion
|
May 11, 2013
Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates
J Michael Soucie, Paul E Monahan, Roshni Kulkarni, et al.
Page
of 13